<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37686322</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>17</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>The Effect of Skeletal Muscle-Specific Creatine Treatment on ALS NMJ Integrity and Function.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">13519</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms241713519</ELocationID><Abstract><AbstractText>Although skeletal muscle (hSKM) has been proven to be actively involved in Amyotrophic Lateral Sclerosis (ALS) neuromuscular junction (NMJ) dysfunction, it is rarely considered as a pharmacological target in preclinical drug discovery. This project investigated how improving ALS hSKM viability and function effects NMJ integrity. Phenotypic ALS NMJ human-on-a-chip models developed from patient-derived induced pluripotent stem cells (iPSCs) were used to study the effect of hSKM-specific creatine treatment on clinically relevant functional ALS NMJ parameters, such as NMJ numbers, fidelity, stability, and fatigue index. Results indicated comparatively enhanced NMJ numbers, fidelity, and stability, as well as reduced fatigue index, across all hSKM-specific creatine-treated systems. Immunocytochemical analysis of the NMJs also revealed improved post-synaptic nicotinic Acetylcholine receptor (AChR) clustering and cluster size in systems supplemented with creatine relative to the un-dosed control. This work strongly suggests hSKM as a therapeutic target in ALS drug discovery. It also demonstrates the need to consider all tissues involved in multi-systemic diseases, such as ALS, in drug discovery efforts. Finally, this work further establishes the BioMEMs NMJ platform as an effective means of performing mutation-specific drug screening, which is a step towards personalized medicine for rare diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Badu-Mensah</LastName><ForeName>Agnes</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NanoScience Technology Center, University of Central Florida, 12424 Research Parkway, Suite 400, Orlando, FL 32826, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xiufang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>NanoScience Technology Center, University of Central Florida, 12424 Research Parkway, Suite 400, Orlando, FL 32826, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendez</LastName><ForeName>Roxana</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>NanoScience Technology Center, University of Central Florida, 12424 Research Parkway, Suite 400, Orlando, FL 32826, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parsaud</LastName><ForeName>Hemant</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>NanoScience Technology Center, University of Central Florida, 12424 Research Parkway, Suite 400, Orlando, FL 32826, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hickman</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>NanoScience Technology Center, University of Central Florida, 12424 Research Parkway, Suite 400, Orlando, FL 32826, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32816, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS050452</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS050452</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>MU72812GK0</RegistryNumber><NameOfSubstance UI="D003401">Creatine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003401" MajorTopicYN="Y">Creatine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018763" MajorTopicYN="N">Muscle Fatigue</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">BioMEMs</Keyword><Keyword MajorTopicYN="N">NMJ</Keyword><Keyword MajorTopicYN="N">SOD1</Keyword><Keyword MajorTopicYN="N">creatine</Keyword><Keyword MajorTopicYN="N">iPSCs</Keyword><Keyword MajorTopicYN="N">microfluidic</Keyword><Keyword MajorTopicYN="N">skeletal muscle</Keyword></KeywordList><CoiStatement>All authors but J.J.H. confirm no existing potential conflict of interest. J.J.H. has ownership interest and is Chief Scientist and member of the Board of Directors in a company that may benefit financially from the outcomes of the research work reported in this publication. &#x201c;The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results&#x201d;.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>9</Day><Hour>11</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>9</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37686322</ArticleId><ArticleId IdType="pmc">PMC10487911</ArticleId><ArticleId IdType="doi">10.3390/ijms241713519</ArticleId><ArticleId IdType="pii">ijms241713519</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsitkanou S., Della Gatta P.A., Russell A.P. Skeletal muscle satellite cells, mitochondria, and micrornas: Their involvement in the pathogenesis of als. Front. Physiol. 2016;7:403. doi: 10.3389/fphys.2016.00403.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2016.00403</ArticleId><ArticleId IdType="pmc">PMC5020084</ArticleId><ArticleId IdType="pubmed">27679581</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Rothstein J.D. Glial cells in amyotrophic lateral sclerosis. Exp. Neurol. 2014;262:111&#x2013;120. doi: 10.1016/j.expneurol.2014.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.05.015</ArticleId><ArticleId IdType="pmc">PMC4241182</ArticleId><ArticleId IdType="pubmed">24859452</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. Als genetics, mechanisms, and therapeutics: Where are we now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Pikatza-Menoio O., Elicegui A., Bengoetxea X., Naldaiz-Gastesi N., L&#xf3;pez de Munain A., Gerenu G., Gil-Bea F.J., Alonso-Mart&#xed;n S. The skeletal muscle emerges as a new disease target in amyotrophic lateral sclerosis. J. Pers. Med. 2021;11:671. doi: 10.3390/jpm11070671.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm11070671</ArticleId><ArticleId IdType="pmc">PMC8307751</ArticleId><ArticleId IdType="pubmed">34357138</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D., Mansfield C., Moussy A., Hermine O. Als clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front. Aging Neurosci. 2017;9:68. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello V., Francolini M. Neuromuscular junction dismantling in amyotrophic lateral sclerosis. Int. J. Mol. Sci. 2017;18:2092. doi: 10.3390/ijms18102092.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18102092</ArticleId><ArticleId IdType="pmc">PMC5666774</ArticleId><ArticleId IdType="pubmed">28972545</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikenaka K., Katsuno M., Kawai K., Ishigaki S., Tanaka F., Sobue G. Disruption of axonal transport in motor neuron diseases. Int. J. Mol. Sci. 2012;13:1225&#x2013;1238. doi: 10.3390/ijms13011225.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms13011225</ArticleId><ArticleId IdType="pmc">PMC3269748</ArticleId><ArticleId IdType="pubmed">22312314</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y.M., Yamamoto M., Kobayashi Y., Yoshihara T., Liang Y., Terao S., Takeuchi H., Ishigaki S., Katsuno M., Adachi H., et al. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann. Neurol. 2005;57:236&#x2013;251. doi: 10.1002/ana.20379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20379</ArticleId><ArticleId IdType="pubmed">15668976</ArticleId></ArticleIdList></Reference><Reference><Citation>Badu-Mensah A., Guo X., McAleer C., Rumsey J., Hickman J.J. Skeletal muscle model derived from familial als patient ipscs recapitulates hallmarks of disease progression. Sci. Rep. 2020;10:14302. doi: 10.1038/s41598-020-70510-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-70510-3</ArticleId><ArticleId IdType="pmc">PMC7459299</ArticleId><ArticleId IdType="pubmed">32868812</ArticleId></ArticleIdList></Reference><Reference><Citation>Picchiarelli G., Demestre M., Zuko A., Been M., Higelin J., Dieterl&#xe9; S., Goy M.A., Mallik M., Sellier C., Scekic-Zahirovic J., et al. Fus-mediated regulation of acetylcholine receptor transcription at neuromuscular junctions is compromised in amyotrophic lateral sclerosis. Nat. Neurosci. 2019;22:1793&#x2013;1805. doi: 10.1038/s41593-019-0498-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0498-9</ArticleId><ArticleId IdType="pmc">PMC6858880</ArticleId><ArticleId IdType="pubmed">31591561</ArticleId></ArticleIdList></Reference><Reference><Citation>Badu-Mensah A., Guo X., Nimbalkar S., Cai Y., Hickman J.J. Als mutations in both human skeletal muscle and motoneurons differentially affects neuromuscular junction integrity and function. Biomaterials. 2022;289:121752. doi: 10.1016/j.biomaterials.2022.121752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2022.121752</ArticleId><ArticleId IdType="pubmed">36084484</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X., Smith V., Jackson M., Tran M., Thomas M., Patel A., Lorusso E., Nimbalkar S., Cai Y., McAleer C.W., et al. A human-based functional nmj system for personalized als modeling and drug testing. Adv. Ther. 2020;3:2000133. doi: 10.1002/adtp.202000133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adtp.202000133</ArticleId><ArticleId IdType="pmc">PMC7942691</ArticleId><ArticleId IdType="pubmed">33709015</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastow E.L., Peswani A.R., Tarrant D.S., Pentland D.R., Chen X., Morgan A., Staniforth G.L., Tullet J.M., Rowe M.L., Howard M.J., et al. New links between sod1 and metabolic dysfunction from a yeast model of amyotrophic lateral sclerosis. J. Cell Sci. 2016;129:4118&#x2013;4129. doi: 10.1242/jcs.190298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.190298</ArticleId><ArticleId IdType="pmc">PMC5117206</ArticleId><ArticleId IdType="pubmed">27656112</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzolino M., Carri M.T. Mitochondrial dysfunction in als. Prog. Neurobiol. 2012;97:54&#x2013;66. doi: 10.1016/j.pneurobio.2011.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2011.06.003</ArticleId><ArticleId IdType="pubmed">21827820</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo G., Yi J., Ma C., Xiao Y., Yi F., Yu T., Zhou J. Defective mitochondrial dynamics is an early event in skeletal muscle of an amyotrophic lateral sclerosis mouse model. PLoS ONE. 2013;8:e82112. doi: 10.1371/journal.pone.0082112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0082112</ArticleId><ArticleId IdType="pmc">PMC3855744</ArticleId><ArticleId IdType="pubmed">24324755</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedemann F.R., Winkler K., Kuznetsov A.V., Bartels C., Vielhaber S., Feistner H., Kunz W.S. Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 1998;156:65&#x2013;72. doi: 10.1016/S0022-510X(98)00008-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(98)00008-2</ArticleId><ArticleId IdType="pubmed">9559989</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Mitchell J.D., Lyon M., Moore D.H. Riluzole for amyotrophic lateral sclerosis (als)/motor neuron disease (mnd) Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2003;4:191&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">13129806</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohta Y., Nomura E., Shang J., Feng T., Huang Y., Liu X., Shi X., Nakano Y., Hishikawa N., Sato K., et al. Enhanced oxidative stress and the treatment by edaravone in mice model of amyotrophic lateral sclerosis. J. Neurosci. Res. 2019;97:607&#x2013;619. doi: 10.1002/jnr.24368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.24368</ArticleId><ArticleId IdType="pubmed">30565312</ArticleId></ArticleIdList></Reference><Reference><Citation>Samaiya P.K., Narayan G., Kumar A., Krishnamurthy S. Tempol (4 hydroxy-tempo) inhibits anoxia-induced progression of mitochondrial dysfunction and associated neurobehavioral impairment in neonatal rats. J. Neurol. Sci. 2017;375:58&#x2013;67. doi: 10.1016/j.jns.2017.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2017.01.021</ArticleId><ArticleId IdType="pubmed">28320189</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavado A., Guo X., Smith A.S.T., Akanda N., Martin C., Cai Y., Elbrecht D., Tran M., Bryant J.-P., Colon A., et al. Evaluation of holistic treatment for als reveals possible mechanism and therapeutic potential. Int. J. Pharm. Pharm. Res. 2017;11:348&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6326589</ArticleId><ArticleId IdType="pubmed">30637316</ArticleId></ArticleIdList></Reference><Reference><Citation>Farshidfar F., Pinder M.A., Myrie S.B. Creatine supplementation and skeletal muscle metabolism for building muscle mass- review of the potential mechanisms of action. Curr. Protein Pept. Sci. 2017;18:1273&#x2013;1287. doi: 10.2174/1389203718666170606105108.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389203718666170606105108</ArticleId><ArticleId IdType="pubmed">28595527</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S.-H., Chen K.-L., Hsu C., Chen H.-C., Chen J.-Y., Yu S.-Y., Shiu Y.-J. Creatine supplementation for muscle growth: A scoping review of randomized clinical trials from 2012 to 2021. Nutrients. 2022;14:1255. doi: 10.3390/nu14061255.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14061255</ArticleId><ArticleId IdType="pmc">PMC8949037</ArticleId><ArticleId IdType="pubmed">35334912</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney E.B., de Winter F., Verhaagen J. Als as a distal axonopathy: Molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the disease. Front. Neurosci. 2014;8:252. doi: 10.3389/fnins.2014.00252.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2014.00252</ArticleId><ArticleId IdType="pmc">PMC4132373</ArticleId><ArticleId IdType="pubmed">25177267</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanjak M., Konopacki R., Capasso R., Roelke K.A., Peper S.M., Houdek A.M., Waclawik A., Brooks B.R. Dissociation between mechanical and myoelectrical manifestation of muscle fatigue in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2004;5:26&#x2013;32. doi: 10.1080/14660820310017551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820310017551</ArticleId><ArticleId IdType="pubmed">15204021</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou J.S., Reeves A., Benice T., Sexton G. Fatigue and depression are associated with poor quality of life in als. Neurology. 2003;60:122&#x2013;123. doi: 10.1212/01.WNL.0000042781.22278.0A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000042781.22278.0A</ArticleId><ArticleId IdType="pubmed">12525733</ArticleId></ArticleIdList></Reference><Reference><Citation>McElhiney M., Rabkin J., Gordon P., Goetz R., Mitsumoto H. Neurosurgery, psychiatry. Prevalence of fatigue and depression in als patients and change over time. J. Neurol. Neurosurg. Psychiatry. 2009;80:1146&#x2013;1149. doi: 10.1136/jnnp.2008.163246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2008.163246</ArticleId><ArticleId IdType="pubmed">19762902</ArticleId></ArticleIdList></Reference><Reference><Citation>Argil&#xe9;s J.M., Campos N., Lopez-Pedrosa J.M., Rueda R., Rodriguez-Ma&#xf1;as L. Skeletal muscle regulates metabolism via interorgan crosstalk: Roles in health and disease. J. Am. Med. Dir. Assoc. 2016;17:789&#x2013;796. doi: 10.1016/j.jamda.2016.04.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2016.04.019</ArticleId><ArticleId IdType="pubmed">27324808</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter R.S., Rosenbohm A., Dupuis L., Brehme T., Kassubek J., Rothenbacher D., Nagel G., Ludolph A.C. Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: Results from the als registry swabia. Eur. J. Epidemiol. 2017;32:901&#x2013;908. doi: 10.1007/s10654-017-0318-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-017-0318-z</ArticleId><ArticleId IdType="pubmed">28975435</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Aucello M., Rizzuto E., Beccafico S., Mammucari C., Boncompagni S., Belia S., Wannenes F., Nicoletti C., Del Prete Z., et al. Skeletal muscle is a primary target of sod1g93a-mediated toxicity. Cell Metab. 2008;8:425&#x2013;436. doi: 10.1016/j.cmet.2008.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2008.09.002</ArticleId><ArticleId IdType="pubmed">19046573</ArticleId></ArticleIdList></Reference><Reference><Citation>Quessada C., Bouscary A., Ren&#xe9; F., Valle C., Ferri A., Ngo S.T., Loeffler J.P. Skeletal muscle metabolism: Origin or prognostic factor for amyotrophic lateral sclerosis (als) development? Cells. 2021;10:1449. doi: 10.3390/cells10061449.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10061449</ArticleId><ArticleId IdType="pmc">PMC8226541</ArticleId><ArticleId IdType="pubmed">34207859</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaricamazza S., Salvatori I., Giacovazzo G., Loeffler J.P., Ren&#xe8; F., Rosina M., Quessada C., Proietti D., Heil C., Rossi S., et al. Skeletal-muscle metabolic reprogramming in als-sod1g93a mice predates disease onset and is a promising therapeutic target. iScience. 2020;23:101087. doi: 10.1016/j.isci.2020.101087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101087</ArticleId><ArticleId IdType="pmc">PMC7200935</ArticleId><ArticleId IdType="pubmed">32371370</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong M., Martin L.J. Skeletal muscle-restricted expression of human sod1 causes motor neuron degeneration in transgenic mice. Hum. Mol. Genet. 2010;19:2284&#x2013;2302. doi: 10.1093/hmg/ddq106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq106</ArticleId><ArticleId IdType="pmc">PMC2865380</ArticleId><ArticleId IdType="pubmed">20223753</ArticleId></ArticleIdList></Reference><Reference><Citation>Deldicque L., Theisen D., Bertrand L., Hespel P., Hue L., Francaux M. Creatine enhances differentiation of myogenic C2C12 cells by activating both p38 and akt/pkb pathways. Am. J. Physiol. Cell Physiol. 2007;293:C1263&#x2013;C1271. doi: 10.1152/ajpcell.00162.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00162.2007</ArticleId><ArticleId IdType="pubmed">17652429</ArticleId></ArticleIdList></Reference><Reference><Citation>McAleer C.W., Smith A.S.T., Najjar S., Pirozzi K., Long C.J., Hickman J.J. Mechanistic investigation of adult myotube response to exercise and drug treatment in vitro using a multiplexed functional assay system. J. Appl. Physiol. 2014;117:1398&#x2013;1405. doi: 10.1152/japplphysiol.00612.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/japplphysiol.00612.2014</ArticleId><ArticleId IdType="pmc">PMC4254839</ArticleId><ArticleId IdType="pubmed">25301895</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulido S.M., Passaquin A.C., Leijendekker W.J., Challet C., Wallimann T., R&#xfc;egg U.T. Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells. FEBS Lett. 1998;439:357&#x2013;362. doi: 10.1016/S0014-5793(98)01399-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(98)01399-4</ArticleId><ArticleId IdType="pubmed">9845353</ArticleId></ArticleIdList></Reference><Reference><Citation>Young J.F., Larsen L.B., Malmendal A., Nielsen N.C., Straadt I.K., Oksbjerg N., Bertram H.C. Creatine-induced activation of antioxidative defence in myotube cultures revealed by explorative nmr-based metabonomics and proteomics. J. Int. Soc. Sports Nutr. 2010;7:9. doi: 10.1186/1550-2783-7-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1550-2783-7-9</ArticleId><ArticleId IdType="pmc">PMC2822831</ArticleId><ArticleId IdType="pubmed">20205771</ArticleId></ArticleIdList></Reference><Reference><Citation>Deldicque L., Atherton P., Patel R., Theisen D., Nielens H., Rennie M.J., Francaux M., Samuelsson H., Moberg M., Apr&#xf3; W., et al. Effects of resistance exercise with and without creatine supplementation on gene expression and cell signaling in human skeletal muscle. J. Appl. Physiol. 2008;104:371&#x2013;378. doi: 10.1152/japplphysiol.00873.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/japplphysiol.00873.2007</ArticleId><ArticleId IdType="pubmed">18048590</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras L., Drago I., Zampese E., Pozzan T. Mitochondria: The calcium connection. Biochim. Biophys. Acta. 2010;1797:607&#x2013;618. doi: 10.1016/j.bbabio.2010.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbabio.2010.05.005</ArticleId><ArticleId IdType="pubmed">20470749</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor R.S., Steeds C.M., Wiseman R.W., Pavlath G.K. Phosphocreatine as an energy source for actin cytoskeletal rearrangements during myoblast fusion. J. Physiol. 2008;586:2841&#x2013;2853. doi: 10.1113/jphysiol.2008.151027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2008.151027</ArticleId><ArticleId IdType="pmc">PMC2517193</ArticleId><ArticleId IdType="pubmed">18420707</ArticleId></ArticleIdList></Reference><Reference><Citation>Busanello E.N.B., Marques A.C., Lander N., de Oliveira D.N., Catharino R.R., Oliveira H.C.F., Vercesi A.E. Pravastatin chronic treatment sensitizes hypercholesterolemic mice muscle to mitochondrial permeability transition: Protection by creatine or coenzyme q10. Front. Pharmacol. 2017;8:185. doi: 10.3389/fphar.2017.00185.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2017.00185</ArticleId><ArticleId IdType="pmc">PMC5380726</ArticleId><ArticleId IdType="pubmed">28424622</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallimann T., Dolder M., Schlattner U., Eder M., Hornemann T., O&#x2019;Gorman E., R&#xfc;ck A., Brdiczka D. Some new aspects of creatine kinase (CK): Compartmentation, structure, function and regulation for cellular and mitochondrial bioenergetics and physiology. Biofactors. 1998;8:229&#x2013;234. doi: 10.1002/biof.5520080310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.5520080310</ArticleId><ArticleId IdType="pubmed">9914824</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokarska-Schlattner M., Epand R.F., Meiler F., Zandomeneghi G., Neumann D., Widmer H.R., Meier B.H., Epand R.M., Saks V., Wallimann T., et al. Phosphocreatine interacts with phospholipids, affects membrane properties and exerts membrane-protective effects. PLoS ONE. 2012;7:e43178. doi: 10.1371/journal.pone.0043178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0043178</ArticleId><ArticleId IdType="pmc">PMC3422282</ArticleId><ArticleId IdType="pubmed">22912820</ArticleId></ArticleIdList></Reference><Reference><Citation>Handschin C., Kobayashi Y.M., Chin S., Seale P., Campbell K.P., Spiegelman B.M. Pgc-1&#x3b1; regulates the neuromuscular junction program and ameliorates duchenne muscular dystrophy. Genes Dev. 2007;21:770&#x2013;783. doi: 10.1101/gad.1525107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1525107</ArticleId><ArticleId IdType="pmc">PMC1838529</ArticleId><ArticleId IdType="pubmed">17403779</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomer X., Alvarez-Guardia D., Rodr&#xed;guez-Calvo R., Coll T., Laguna J.C., Davidson M.M., Chan T.O., Feldman A.M., V&#xe1;zquez-Carrera M. Tnf-&#x3b1; reduces pgc-1 &#x3b1; expression through nf-&#x3ba;b and p38 mapk leading to increased glucose oxidation in a human cardiac cell model. Cardiovasc. Res. 2009;81:703&#x2013;712. doi: 10.1093/cvr/cvn327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvn327</ArticleId><ArticleId IdType="pubmed">19038972</ArticleId></ArticleIdList></Reference><Reference><Citation>Safdar A., Yardley N.J., Snow R., Melov S., Tarnopolsky M.A. Global and targeted gene expression and protein content in skeletal muscle of young men following short-term creatine monohydrate supplementation. Physiol. Genom. 2008;32:219&#x2013;228. doi: 10.1152/physiolgenomics.00157.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiolgenomics.00157.2007</ArticleId><ArticleId IdType="pubmed">17957000</ArticleId></ArticleIdList></Reference><Reference><Citation>Santhanam N., Kumanchik L., Guo X., Sommerhage F., Cai Y., Jackson M., Martin C., Saad G., McAleer C.W., Wang Y., et al. Stem cell derived phenotypic human neuromuscular junction model for dose response evaluation of therapeutics. Biomaterials. 2018;166:64&#x2013;78. doi: 10.1016/j.biomaterials.2018.02.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2018.02.047</ArticleId><ArticleId IdType="pmc">PMC5866791</ArticleId><ArticleId IdType="pubmed">29547745</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X., Das M., Rumsey J.W., Gonzalez M., Stancescu M., Hickman J.J. Neuromuscular junction formation between human stem cell derived motoneurons and rat skeletal muscle in a defined system. Tissue Eng. Part. C Methods. 2010;16:1347&#x2013;1355. doi: 10.1089/ten.tec.2010.0040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ten.tec.2010.0040</ArticleId><ArticleId IdType="pmc">PMC2988647</ArticleId><ArticleId IdType="pubmed">20337513</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond L. Measuring Cell Fluorescence Using Imagej. 2014.  [(accessed on 1 June 2023)].  Available online:  https://theolb.readthedocs.io/en/latest/imaging/measuring-cell-fluorescence-using-imagej.html.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>